Zymeworks Inc (NAS:ZYME)
$ 9.07 -0.31 (-3.3%) Market Cap: 641.29 Mil Enterprise Value: 343.39 Mil PE Ratio: 0 PB Ratio: 1.46 GF Score: 78/100

Zymeworks Inc at Barclays Global Healthcare Conference Transcript

Mar 14, 2023 / 02:45PM GMT
Release Date Price: $8.47 (+2.67%)
Kenneth H. Galbraith
Zymeworks Inc. - CEO & Chairman of the Board

Great. Good morning, everyone. My name is Ken Galbraith. I'm the Chair and CEO of Zymeworks. I want to thank Barclays for the opportunity to come to Miami Beach and present our story to you today. First of all, this is our forward-looking statement, as you see here. I encourage you to read it with a bigger print, and I can encourage you to go to our website and look at our SEC filings.

So trying to summarize Zymeworks one slide for you here. So our work is focused on kind of the power of multifunctional therapeutics, initially on oncology but eventually beyond.

So essentially, we work as an integrated R&D engine that is capable of generating 2 different types of multifunctional therapeutics, and then we use those as a crossover as well, but to the different platforms, which I'll talk about. First, we start on with a focus on the worst patient prognosis, like the difficult-to-treat cancers, those with the lowest 5-year overall survival rate. We focus on those indications. We find a target or a pair of targets we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot